


Linzagolix

Cat. No.:	HY-109093		
CAS No.:	935283-04-8		
Molecular Formula:	C ₂₂ H ₁₅ F ₃ N ₂ O ₇ S		
Molecular Weight:	508.42		
Target:	GnRH Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (245.86 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.9669 mL	9.8344 mL	19.6688 mL
5 mM	0.3934 mL	1.9669 mL	3.9338 mL
10 mM	0.1967 mL	0.9834 mL	1.9669 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Linzagolix (KLH-2109; OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. Linzagolix can be used for uterine fibroids, endometriosis, adenomyosis research^[1].

REFERENCES

[1]. Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA